Immuneering Announces Participation in February Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Wall Street dips as surging Treasury yields outweigh software gains
- Oil prices rise as China suspends fuel exports
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Elevated equity positioning, leverage could challenge stocks in Q4: JPMorgan
- Alphabet shares up in premarket trade after Gemini 4 Argon launch
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
Teva Pharma (TEVA) Mentioned Positively at Oppenheimer
February 5, 2024 5:45 AM ESTOppenheimer analyst Leland Gershell reiterated a Perform rating on Teva Pharma (NYSE: TEVA).
The analyst comments "4Q23 top- and bottom-line beats were helped by SNY's $500M upfront for TL1A that Street models may not have adequately reflected. Nonetheless, we are... More
